Next Generation Bio Innovation 2025

Examples to highlight three key areas of differential product-driven value creation TABLE 1 Sour ce: World Economic Forum analysis, Bioeconomy Community inputProduct-driven value cr eation Bio-impr oved productHyalur onic acid Traditionally extracted fr om rooster combs, hyalur onic acid (HLA) is now primarily pr oduced by micr obial fermentation. Bio-pr oduced HLA is animal-component fr ee, has lower production costs, r educed envir onmental pollution and tailorable molecular weights.6 With growing consumer demand, the global HA market size is calculated to be $11.14 billion in 2025.7 Bio-superior productsHybrid maize TELA hybrid maize varieties ar e genetically engineer ed for impr oved insect r esistance and dr ought tolerance, and up to 60% incr ease in yield. Most r ecently in February 2025, Ethiopia joined South Africa, Nigeria and Kenya to appr ove the commer cialization of biotech maize, supporting millions of farmers acr oss Africa.10Chymosin Chymosin gained US Food and Drug Administration (FDA) appr oval in 1990.8 Originally sour ced fr om calf r ennet, chymosin is alter natively produced fr om engineer ed yeast. The majority of har d cheese in the US and the United Kingdom uses fermented chymosin,9 providing a vegetarian, ethical alter native. Business value examples Consumer value examples Sicilian Rouge tomato Sanatech Seed’ s Sicilian Rouge tomato variety is engineer ed using the CRISPR-Cas9 technology to increase levels of gamma- aminobutyric acid (GABA), claimed to support lower blood pr essur e and pr omote r elaxation. Fr om development to commer cialization in Japan in just two years, its online sales began in September of 2022.11 Bio-disruptive productsNitrogen-fixing micr obes As of 2024, Pivot Bio’ s nitr ogen- fixing micr obial pr oducts, which can replace up to 25% of traditional fertilizer usage, wer e used on over 5 million acr es of US farmland. W ith just 2% of the emissions of synthetic fertilizer and manufactur ed with 1,000 times less water , the potential operational value is substantial.12CAR-T therapies Personalized CAR-T therapies, such as those pr ovided by Novartis,13 provide targeted cancer tr eatments with impr oved efficacy and increased specificity compar ed to traditional appr oaches.14 The global CAR-T cell therapy market for drugs with Kymriah’ s indications was valued at $4.38 billion in 2023 and is pr ojected to gr ow to $16.35 billion by 2032.15 Next Generation Bio-Innovation: Delivering Commercial Value 8